Aktis Oncology (NASDAQ:AKTS) Given Consensus Recommendation of “Buy” by Analysts

Aktis Oncology (NASDAQ:AKTS) has received a consensus rating of “Buy” from the five brokerages that are covering the company, MarketBeat.com reports. Five investment analysts have rated the stock with a buy recommendation. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $31.25.

AKTS has been the topic of a number of recent research reports. TD Cowen began coverage on Aktis Oncology in a research report on Tuesday, February 3rd. They set a “buy” rating on the stock. JPMorgan Chase & Co. assumed coverage on Aktis Oncology in a report on Tuesday, February 3rd. They issued an “overweight” rating and a $30.00 target price for the company. HC Wainwright assumed coverage on Aktis Oncology in a research report on Monday, March 9th. They set a “buy” rating and a $30.00 target price on the stock. Leerink Partners began coverage on Aktis Oncology in a report on Tuesday, February 3rd. They set an “outperform” rating and a $31.00 price target on the stock. Finally, Bank of America initiated coverage on shares of Aktis Oncology in a research note on Tuesday, February 3rd. They set a “buy” rating and a $34.00 price objective for the company.

Insider Transactions at Aktis Oncology

In other news, Director Ecor1 Capital, Llc purchased 2,222,222 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The stock was purchased at an average cost of $18.00 per share, with a total value of $39,999,996.00. Following the purchase, the director owned 4,348,658 shares in the company, valued at approximately $78,275,844. This trade represents a 104.50% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Bioventures 2018 L.P. Mpm purchased 1,112,777 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $20,029,986.00. Following the completion of the acquisition, the insider directly owned 10,260,064 shares in the company, valued at $184,681,152. The trade was a 12.17% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have purchased 6,117,776 shares of company stock worth $110,119,968.

Aktis Oncology Stock Performance

Shares of NASDAQ AKTS opened at $18.99 on Monday. Aktis Oncology has a 12-month low of $16.80 and a 12-month high of $29.16. The firm’s 50-day simple moving average is $19.71.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.